<DOC>
	<DOCNO>NCT01225341</DOCNO>
	<brief_summary>The purpose study determine efficacy safety Botulinum Toxin Type A preventative measure Herpes Labialis .</brief_summary>
	<brief_title>Botulinum Toxin A Herpes Labialis</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Males female age 18 64 . Have herpes simplex virus 1 ( HSV1 ) 26 herpes labialis recurrence per year . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study . Subjects childbearing potential must negative urine pregnancy test result Visit 1 willing able use acceptable method birth control ( e.g. , barrier method use spermicidal agent , hormonal method , IUD , surgical sterilization , abstinence ) study . Women consider childbearing potential one follow document medical history : postmenopausal least 12 month prior study drug administration without uterus and/or ovary bilateral tubal ligation least 6 month prior study drug administration . absence physical condition accord PI 's discretion Willingness ability provide write photo consent adherence photography procedure ( i.e. , removal jewelry makeup ) . Willingness ability provide write informed consent prior performance study related procedure . Subjects pregnant , nursing , plan become pregnant , and/or use reliable form birth control . Subjects know allergy sensitivity component study medication anesthesia . Active recurrence herpes labialis . Botulinum toxin low 1/3 face past 6 month . Significant concurrent illness diabetes , epilepsy , lupus , congestive heart failure . Concurrent skin condition affect area treat . Prior surgery area treat within 3 month initial treatment study . History evidence keloid hypertrophic scar . Current use antiviral treatment herpes labialis within 2 week prior initiation treatment ( e.g. , acyclovir , valaciclovir , famciclovir , penciclovir ) . Topical use overthecounter medication treatment prevention HSV1 ( e.g. , Abreva ) . Subjects currently use aminoglycoside antibiotic , curarelike agent agent might interfere neuromuscular function . Subjects diagnosis Myasthenia Gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis , disease might interfere neuromuscular function current facial palsy . Current history chronic drug alcohol abuse . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study medication . Subjects , Investigator 's opinion , history poor cooperation , noncompliance medical treatment unreliability . Enrollment active study involve use investigational device drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HSV-1</keyword>
	<keyword>Herpes labialis</keyword>
	<keyword>Cold sore</keyword>
	<keyword>Fever blister</keyword>
</DOC>